title: Prognostic factors and clinical outcomes of urological soft tissue sarcomas.
abstract: OBJECTIVE
  The purpose of this study was to elucidate prognostic factors for survival and clinical outcomes of rological soft tissue sarcomas (STSs).
  
  
  METHODS
  This was a retrospective review of the medical records of 48 patients with urological STS treated from January 1982 to July 2009. Demographic and pathological characteristics were compared. Patients' demographics, clinico-pathological parameters, overall survival, and the factors expected to predict survival, such as sex, age at diagnosis, primary organ, surgical resection, metastasis, and mass size, were analyzed. We evaluated differences in survival on the basis of histological subtype by Kaplan-Meier analysis and multivariate Cox proportional hazards regression.
  
  
  RESULTS
  The study included 34 males (70.8%) and 14 females (29.1%). The mean age at diagnosis was 47.1 years (range, 3 to 80). The most common site was the retroperitoneum (n=16), followed by the kidney (n=12), prostate (n=10), bladder (n=7), ureter (n=1), and paratesticular region (n=1). Nineteen patients (39.5%) had other organ metastases at diagnosis. The most common subtypes of sarcoma were leiomyosarcoma (50%), rhabdomyosarcoma (18.7%), and liposarcoma (8%). The remaining 11 cases had other histological subtypes (22.9%). Mean tumor size was 9.5 cm (range, 2.2 to 24). Thirty-three patients (68.7%) underwent surgical resection. The overall survival rate at 5 years was 51.4%. In the univariate and multivariate analysis, surgical resection, primary tumor site, and metastasis at diagnosis remained significant predictors of prognosis. Patients with retroperitoneal sarcoma had a higher overall survival rate by 5 years compared with patients with other organ sarcoma.
  
  
  CONCLUSIONS
  The overall survival rate at 5 years was 51.4%. Surgical resection, primary tumor site, and metastasis at diagnosis remained significant predictors of prognosis.
authors.affiliation: Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: Geonseok
authors.initials: G
authors.lastname: Lee
authors.forename: Seo Yeon
authors.initials: SY
authors.lastname: Lee
authors.forename: Seongil
authors.initials: S
authors.lastname: Seo
authors.forename: Seongsoo
authors.initials: S
authors.lastname: Jeon
authors.forename: Hyunmoo
authors.initials: H
authors.lastname: Lee
authors.forename: Hanyong
authors.initials: H
authors.lastname: Choi
authors.forename: Byong Chang
authors.initials: BC
authors.lastname: Jeong
references.citation: Urol Int. 2010;84(3):309-14
references.pmid: 20389161
references.citation: J Urol. 1992 Apr;147(4):1032-6; discussion 1036-7
references.pmid: 1552580
references.citation: J Urol. 2006 Nov;176(5):2033-8; discussion 2038-9
references.pmid: 17070247
references.citation: Ann Surg. 1998 Sep;228(3):355-65
references.pmid: 9742918
references.citation: J Surg Res. 2007 Jul;141(1):105-14
references.pmid: 17512548
references.citation: Tumori. 2008 Jul-Aug;94(4):497-504
references.pmid: 18822685
references.citation: Ann Surg Oncol. 2007 Mar;14(3):1114-22
references.pmid: 17206483
references.citation: J Clin Oncol. 2002 Nov 1;20(21):4344-52
references.pmid: 12409334
references.citation: Ann Surg Oncol. 1999 Jan-Feb;6(1):57-69
references.pmid: 10030416
references.citation: Ann Surg. 2006 Sep;244(3):381-91
references.pmid: 16926564
references.citation: Eur Urol. 2005 Apr;47(4):468-73
references.pmid: 15774243
references.citation: CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
references.pmid: 15661684
references.citation: J Urol. 1989 May;141(5):1107-10
references.pmid: 2540348
references.citation: Int J Clin Oncol. 2010 Aug;15(4):399-405
references.pmid: 20379757
references.citation: Eur J Surg Oncol. 2007 Mar;33(2):234-8
references.pmid: 17081725